Skip to Main Content
TABLE 1

Subject characteristics

Nondiabetic (n = 9)Type 2 diabetic (n = 10)
Age (years) 55 ± 3 59 ± 1 
BMI (kg/m226.6 ± 0.6 27.7 ± 0.8 
Body fat (%) 22.9 ± 1.9 25.4 ± 1.9 
Waist (cm) 96 ± 2 102 ± 2 
Hip (cm) 100 ± 2 101 ± 1 
Waist-to-hip ratio 0.96 ± 0.02 1.0 ± 0.01 
Vo2max (ml · kg fat free mass−1 · min−146.2 ± 2.2 39.2 ± 2.7 
HbA1c (%) 4.6 ± 0.1 5.9 ± 0.4 
GIR (μmol · kg−1 · min−134.3 ± 3.1 16.7 ± 2.6* 
Glucose (mmol/l) 5.6 ± 0.1 9.0 ± 0.5* 
Insulin (mU/1) 5 ± 1 10 ± 1 
C-peptide (nmol/l) 0.62 ± 0.05 0.99 ± 0.11 
Cholesterol (mmol/l) 5.3 ± 0.3 4.6 ± 0.2 
Triglyceride (mmol/l) 1.4 ± 0.3 1.5 ± 0.2 
HDL (mmol/l) 1.22 ± 0.06 1.12 ± 0.07 
LDL (mmol/l) 3.4 ± 0.3 2.8 ± 0.1 
Duration of diabetes (years) — 5 ± 1 
Nondiabetic (n = 9)Type 2 diabetic (n = 10)
Age (years) 55 ± 3 59 ± 1 
BMI (kg/m226.6 ± 0.6 27.7 ± 0.8 
Body fat (%) 22.9 ± 1.9 25.4 ± 1.9 
Waist (cm) 96 ± 2 102 ± 2 
Hip (cm) 100 ± 2 101 ± 1 
Waist-to-hip ratio 0.96 ± 0.02 1.0 ± 0.01 
Vo2max (ml · kg fat free mass−1 · min−146.2 ± 2.2 39.2 ± 2.7 
HbA1c (%) 4.6 ± 0.1 5.9 ± 0.4 
GIR (μmol · kg−1 · min−134.3 ± 3.1 16.7 ± 2.6* 
Glucose (mmol/l) 5.6 ± 0.1 9.0 ± 0.5* 
Insulin (mU/1) 5 ± 1 10 ± 1 
C-peptide (nmol/l) 0.62 ± 0.05 0.99 ± 0.11 
Cholesterol (mmol/l) 5.3 ± 0.3 4.6 ± 0.2 
Triglyceride (mmol/l) 1.4 ± 0.3 1.5 ± 0.2 
HDL (mmol/l) 1.22 ± 0.06 1.12 ± 0.07 
LDL (mmol/l) 3.4 ± 0.3 2.8 ± 0.1 
Duration of diabetes (years) — 5 ± 1 

GIR, glucose infusion rate during 120–180 min of the euglycemic-hyperinsulinemic clamp.

*

P < 0.001,

P < 0.01,

P < 0.02 versus nondiabetic subjects.

Close Modal

or Create an Account

Close Modal
Close Modal